Ravindra Majeti

Dr. Majeti is generating cell-based models to test the progression of preleukemic cells into acute myeloid leukemia (AML). His lab will use these models to test potential therapies and the role of the microenvironment in disease progression.

Ravi Majeti MD, PhD is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, MD, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >100 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and The Leukemia & Lymphoma Society Scholar Award. Dr. Majeti is currently a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and serves of the editorial boards of Blood, eLife, and Cancer Discovery.